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Abstract
Damage to the heart can result from both traditional chemotherapeutic agents, such as
doxorubicin, and newer ‘targeted’ therapies, such as trastuzumab. This chemotherapeutic
cardiotoxicity is potentially life-threatening and necessitates limiting or discontinuing an
otherwise-effective cancer treatment. Clinical strategies focus on surveillance rather than
prevention, although there are no specific therapies for this highly morbid adverse effect. Current
models for prospectively predicting risk of chemotherapeutic cardiotoxicity are limited.
Cardiotoxicity can occur idiosyncratically in patients without obvious demographic risk factors,
suggesting a genetically determined susceptibility, and candidate-gene studies have identified a
limited number of variants that increase risk. In this commentary we indicate a need for more
powerful means to identify risk prospectively, and suggest that broad pharmacogenomic
approaches may be fruitful.
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Cancer is a collection of diseases caused by the dysregulated proliferation of various cell
types. Drugs that treat cancer either broadly inhibit cellular proliferation or specifically
target proteins that are essential to expanding the population of abnormal cells. In contrast to
many other tissue types, heart muscle has a very limited capacity for cellular proliferation.
Its functional constituent cell type – the cardiomyocyte – is terminally differentiated and
incapable of division. Thus, the development of cardiotoxicity in response to numerous
chemotherapeutic agents is somewhat surprising from a biological perspective.
Nevertheless, patients who receive these agents are at increased risk of sustaining heart
damage, which ranges from asymptomatic decrease in contractile function to overt heart
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failure and death. In this article, we consider the cardiotoxicity associated with
anthracyclines, a traditional class of antineoplastic agents, as well as trastuzumab and other
newer drugs with a specific molecular target. Despite considerable efforts toward
understanding the determinants of risk, clinicians remain unable to ascertain prospectively
which patients will develop these life-threatening adverse reactions. We conclude that there
is a pressing need to develop novel strategies to identify patients at high risk for
chemotherapeutic cardiotoxicity.
Anthracyclines: the past & present of chemotherapeutic cardiotoxicity
Doxorubicin (Adriamycin) and the related compounds daunorubicin and epirubicin are
anthracycline antibiotics with broad antineoplastic activity, at least partially mediated by
DNA intercalation and inhibition of topoisomerase II [1]. Their efficacy in the treatment of
hematologic malignancies first was demonstrated in the 1960s [2,3], and doxorubicin in
particular has been a mainstay of therapy for leukemia, lymphoma, breast cancer and
numerous other malignancies for decades. The potency of anthracyclines was well
illustrated in a meta-analysis published in 2005, which showed that use of an anthracycline-
based chemotherapeutic regimen for the treatment of breast cancer reduces the annual
disease-related mortality by 38% in women younger than 50 and by 20% in women between
50 and 70 years of age [4].
The cardiotoxicity of this highly effective class of chemotherapy was not predicted in
preclinical studies [5,6] and initially was thought to be limited to children receiving
especially high doses of the drug. Subsequently, however, the identification of fatal heart
failure in multiple adults treated with ostensibly ‘safe’ doses of these drugs led some early
investigators to suggest limiting their use to patients less than 40 years of age [7]. Further
experience demonstrated a proportional increase in the risk of cardiotoxicity with higher
cumulative dose [8] leading to a decrease in the incidence of this dreaded complication, but
cardiomyopathy and heart failure continue to occur in both children and adults who receive
doxorubicin [9]. Even low-dose regimens carry at least 5–15% risk of cardiotoxicity [10,11],
and clinical trial data likely underestimate the burden of cardiotoxicity owing to overly
narrow definitions or limited follow-up intervals [12]. In fact, as many as 50% of patients
who receive doxorubicin may develop subclinical cardiac damage [10,13]. Importantly, even
asymptomatic left-ventricular dysfunction carries substantial risk of subsequent heart failure
and death [14]. As survivorship and longitudinal follow-up intervals increase [15–17], the
population of doxorubicin recipients ages and the associated cardiac morbidity and mortality
can be expected to increase [18].
Despite decades of investigation, the mechanisms underlying doxorubicin-induced
cardiotoxicity remain incompletely understood [19]. Ample experimental evidence
(reviewed in [20,21]) demonstrate contributions to anthracycline-related cardiomyocyte
death from both oxidative stress [22–26] and enhancement of proapoptotic signaling
pathways [27–32], as well as failure of DNA-repair mechanisms and direct damage to the
cardiac sarcomere [21]. Multiple clinical trials have demonstrated cardioprotection from the
iron-chelating agent dexrazoxane [33,34] and mouse models have suggested that disruptions
in iron-handling pathways may predispose to doxorubicin-induced cardiotoxicity [35]. The
limitations of our mechanistic understanding of this process are manifest in the lack of
effective means to predict its occurrence. The most common surveillance strategies for the
detection of incident cardiomyopathy consist of serial cardiac imaging using
echocardiography or radionuclide angiography [36]. Although these measures are relatively
sensitive and surveillance should be practiced universally, they may simply alert physicians
to the presence of irreversible damage. Newer molecular imaging techniques may prove
more sensitive for the detection of early damage, but there currently are no molecular means
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to prospectively and specifically identify patients at risk. Some centers also follow serial
cardiac biomarkers, such as cardiac troponin and natriuretic peptides, in patients who
receive anthracyclines. Although small studies suggest merit to this approach [37], there are
no prospective data demonstrating the efficacy or cost–effectiveness of cardiac biomarker
surveillance in mitigating risk of anthracycline-induced cardiotoxicity.
Management of anthracycline-induced cardiomyopathy consists of neurohormonal
antagonism with ACE inhibitors and β-adrenergic receptor antagonists (β-blockers),
although patients often experience progressive heart failure despite these agents. This
practice has been extrapolated from abundant evidence of decreased morbidity and mortality
in heart failure patients treated with these neurohormonal antagonists, and likely is
underused in chemotherapeutic cardiotoxicity [38]. Although dexrazoxane has demonstrated
efficacy, uptake of this strategy has been rather limited. US FDA guidelines advise
discontinuation of doxorubicin in the event of significant objective deterioration of cardiac
function.
The unanticipated cardiotoxicity of ‘targeted’ therapies
The accelerating pace of discovery brought numerous novel chemotherapeutic agents to
market in the past decade. This new generation of therapies was developed to augment or
replace a host of ‘traditional’ chemotherapeutic agents, such as anthracyclines, with variable
efficacies and broad toxicities. Many of these targeted therapies have significantly more
favorable safety and tolerability profiles; however, unanticipated adverse effects have been
identified. One of the more salient and troubling adverse effects associated with multiple
new chemotherapeutic agents is cardiotoxicity (Table 1). Over a decade ago, it became
apparent that a surprising and significant number of patients were developing a
cardiomyopathy associated with trastuzumab – the humanized monoclonal antibody
targeting HER2 (also known as ErbB2) [39,40]. This unexpected complication detracts from
the otherwise-impressive tolerability and exceptional efficacy of this agent, which
meaningfully extends disease-free survival in women with HER2+ breast cancer [39,41,42].
Although clinical trials report significantly lower incidence [41], it is likely that
trastuzumab-associated cardiotoxicity occurs in roughly 20–33% of patients who receive the
drug [12,43–45]. The resultant cardiomyopathy is often mild and reversible – particularly
with increased dosing intervals between the anthracycline and trastuzumab – although its
long-term implications on cardiovascular morbidity and mortality are unclear. Recent
publication of NSABP B-31 clinical trial data demonstrate that the majority of the
approximately 10% of subjects who developed trastuzumab-associated cardiotoxicity during
the initial trial period had normal cardiac function at the 7-year follow-up [46]. However,
longitudinal follow-up now suggests that the myocardial damage can be both severe and
chronic [43,45].
Importantly, the reaction appears to be idiosyncratic and independent of cumulative dose.
The risk of developing cardiotoxicity is likely enhanced by the concomitant use of
doxorubicin, and is more common in older patients with cardiac comorbidities [20,47]. The
current approach for surveillance of cardiac damage is patterned after the approach used in
anthracycline recipients, employing echocardiography and occasionally cardiac biomarkers.
At present, there are no evidence-based therapies for trastuzumab-related cardiotoxicity, and
its detection frequently leads to dose modification or even discontinuation of an otherwise
highly effective treatment for breast cancer [46]. Given its impressive efficacy in the
treatment of HER2+ breast cancer, trastuzumab will likely continue to be a cornerstone of
adjuvant chemotherapy, underscoring the importance of both mechanistic study and further
longitudinal cardiac outcomes data to guide prospective clinical decision-making.
Jensen and McLeod Page 3













Trastuzumab-associated cardiotoxicity is incompletely understood but apparently does not
lead to short-term loss of cardiomyocytes or significant ultrastructural myocardial
abnormalities [48]. This, and other apparent distinctions, have led some to categorize
trastuzumab-associated cardiotoxicity as a ‘type II’ effect, as opposed to the irreversible,
‘type I’ effect associated with anthracyclines [36]. The mechanism of trastuzumab-
associated cardiotoxicity remains unclear, although its emergence gave rise to a biologically
meaningful body of work that has described the importance of the neuregulin-1–ErbB2
signaling axis in the heart [49]. In many respects, the investigation of this signaling axis has
generated a revised paradigm wherein the heart is now understood to be a functionally
pluricellular organ, rather than a collection of cardiomyocytes structurally supported by
fibroblasts. In this framework, cardiomyocyte receptors (e.g., ErbB2) participate in complex
regulatory crosstalk with endothelial cells and fibroblasts via paracrine stimuli (e.g.,
neuregulin). This expanded recognition of the important roles of ‘nonmyocytes’ in the heart
has broadly enhanced our understanding of myocardial biology and may also shed light on
previously unrecognized mechanisms of drug-induced cardiotoxicity.
Multiple new chemotherapeutic agents selectively targeting tyrosine kinases have been
introduced in recent years and their clinical applications have been expanding. It was hoped
that the specificity of these small molecules – including imatinib, sunitinib, dasatinib and
nilotinib – for a chosen tyrosine kinase would minimize adverse effects; however, sunitinib
causes clinically apparent cardiotoxicity [50], and emerging data on other members of the
class suggest a similar potential [51,52]. More recently it also has become evident that
bevacizumab, a monoclonal antibody to VEGF-A, also is associated with cardiomyopathy
and heart failure [53].
The myocardial damage induced by these ostensibly targeted therapies likely results from
the cumulative response to both ‘on-target’ and ‘off-target’ effects. The on-target adverse
events reflect the medical and scientific community’s incomplete understanding of the
biological roles of the target molecule. The off-target toxicities result from an incomplete
characterization of the biological action of the drug itself. The efficacy of these compounds
– and the lack of appealing extant therapeutic options – understandably brings them to
market more quickly than drugs with other disease targets. The relatively brief period of
time between development and clinical uptake emphasizes the critical importance of
developing risk-stratification measures that will maximize therapeutic benefit and minimize
both predictable and unpredictable harm. Achieving this balance requires both developing
the ‘right’ drug, and selecting the appropriate patients to receive that drug. Recently,
investigators introduced a novel preclinical strategy to predict tyrosine kinase inhibitor
toxicity using zebrafish, and proposed that this clever approach would be useful in
determining the cardiac toxicity of future drug candidates [54]. However, at present, our
ability to prospectively identify patients at high risk for the development of
chemotherapeutic cardiotoxicity remains limited.
Risk stratification: clinical & demographic profiling
The likelihood of developing cardiomyopathy secondary to doxorubicin is increased by
higher cumulative dose [8], concomitant irradiation [55], cardiovascular comorbidities [56],
age >65 years [10] and female sex [57]. Advanced age and cardiovascular comorbidities
also appear to increase the likelihood of developing trastuzumab-associated cardiotoxicity
[58], and concomitant administration of doxorubicin clearly increases risk [39]. Sunitinib-
associated cardiotoxicity also appears to occur with greater frequency in older patients with
pre-existing cardiac disease [50]. Such demographic profiles are blunt instruments for risk
assessment, and it would be both impractical and medically disadvantageous to limit the use
of these highly efficacious chemotherapeutic agents to young patients without comorbidities.
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Given the ever-expanding population of patients with both cardiac risk factors and cancer,
there is a pressing need for more sophisticated tools to stratify risk for chemotherapeutic
cardiotoxicity.
Importantly, a significant number of adverse effects occur in patients without obvious risk
factors. For example, some patients develop profound anthracycline-induced cardiotoxicity
at low doses of doxorubicin, whereas other patients tolerate very high doses without any
myocardial damage [59]. There is no clear relationship between cumulative dose of
trastuzumab and the likelihood of developing cardiotoxicity [43], and the adverse cardiac
effects of tyrosine kinase inhibitors are likely to be similarly idiosyncratic [60]. The
incomplete prediction of adverse response by demographic and clinical factors bespeaks a
predisposition to susceptibility that may well be genetically determined. Pharmacogenetic
profiling of chemotherapeutic cardiotoxicity has to date been limited, but holds promise as a
means to maximize anticancer benefit and minimize cardiotoxic harm.
Risk stratification: candidate-gene approaches
Extant knowledge of the genetic determinants of susceptibility to the cardiotoxicity of
trastuzumab and other targeted therapies is limited. Candidate-gene approaches naturally
have focused on variants in the molecular targets for these drugs, although this approach
clearly underestimates their mechanistic complexity. One small study suggested that an
ErbB2 polymorphism (Ile655Val) conferred both increased growth potential in tumor cells
and an increased propensity for cardiotoxicity in patients treated with trastuzumab [61].
However, it is unlikely that a single, common variant is sufficient to explain the risk of this
untoward effect.
Numerous investigators have employed a candidate-gene approach to genotyping risk for
doxorubicin-induced cardiotoxicity. In each case, the selection of SNPs has been guided by
the presumed mechanism of myocardial injury, by knowledge of the pathways responsible
for doxorubicin trafficking and elimination, or by demonstration of inducible protection
against anthracycline-induced cardiotoxicity (Figure 1) [62]. Although this approach has met
with some success, it inherently is limited by the incomplete understanding of the
mechanisms underlying the myocardial insult.
Animal studies have suggested critical roles for numerous genes involved in oxidative stress,
including Nox2 [22], NOS2a, MnSOD [23], PTGS2 [24], MT [25] and TRX1 [26]. Genes
involved in the metabolism of doxorubicin also have been implicated in mouse models, such
as CBR1, CBR3 [63] and ABCB1/MDR1 [64]. Transgenic mice also have helped to identify
the roles of STAT3 [29] and GATA4 [27,28] in the transcriptional regulation of the response
to doxorubicin-induced myocardial injury. Although such studies may provide some insight
regarding the effect of dramatic alterations in the abundance or function of a given protein,
they rarely predict a response in the human system. Among the variety of reasons for this
discordance, perhaps the most important is the fact that human gene variants rarely result in
either the complete failure of protein expression (as in a knockout mouse) or the
supraphysiologic levels of overexpression seen in many transgenic mouse models. Thus,
candidate-gene approaches to identify determinants of chemotherapeutic cardiotoxicity have
not been particularly fruitful, with a few noteworthy exceptions.
One such study evaluated SNPs from 82 genes with a ‘conceivable role in anthracycline
cardiotoxicity’ [65]. The authors selected candidate-gene variants based on their role in
reactive oxygen species generation, doxorubicin transport or metabolism, and in the
development of heart failure due to other causes. Subjects were adults (mean age: 62 years)
drawn from the German High-Grade Non-Hodgkin Lymphoma Study Group who developed
either chronic or acute cardiotoxicity after a cumulative doxorubicin dose of 300 mg/m2.
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The authors identified five variants in genes encoding either NADPH oxidase subunits or
doxorubicin efflux transporter ABCB1/MDR1 that conveyed up to 2.5-fold increased risk
for cardiotoxicity.
A subsequent study from a separate group confirmed an increased susceptibility to
doxorubicin-induced cardiotoxicity in patients with the −212A>G variant of the gene
encoding the NCF4 subunit of NADPH oxidase [66]. Smaller candidate-gene studies have
implicated variants in other genes encoding parts of the doxorubicin metabolism pathway
(CBR1 and CBR3 [67], as well as ABCC1 [68]). However, others failed to find an increased
risk associated with variants in numerous genes involved in oxidative homeostasis [69].
More recently, Visscher et al. published the largest effort to date investigating genetic
determinants of doxorubicin-induced cardiotoxicity on behalf of the Canadian
Pharmacogenomics Network for Drug Safety Consortium [70]. The authors studied 2977
SNPs in 220 drug biotransformation genes in a discovery cohort and two separate replication
cohorts in Canada and The Netherlands. The subjects were children who received
anthracyclines for the treatment of various malignancies and developed cardiotoxicity
during at least 5 years of follow-up. A synonymous coding variant in the solute SLC28A3 or
hCNT3 gene conferred significant protection (odds ratio: 0.31) against doxorubicin-induced
cardiotoxicity. Multiple variants in ABCB1, ABCB4 and ABCC1 also were found to be
protective. Based on these results, the investigators developed a multigene risk-stratification
tool and retrospectively used it to group the discovery and replication cohorts in tertiles of
risk. The positive predictive value for classification as high risk was 75% and the negative
predictive value for low-risk classification was 96%.
Interestingly, this study failed to confirm the previously published association between
susceptibi lity to doxorubicin-induced cardiotoxicity and variants in ABCC1 and NCF4
[65,66]. The discrepancy may arise from the fact that the previous studies analyzed SNPs
from adult patients, whereas Visscher et al. assayed a pediatric population. The differences
between adult and pediatric susceptibility to doxorubicin have been recognized for over four
decades [7] and likely limit the applicability of these findings to the adult population. There
are also important ascertainment differences, with Visscher et al. accruing from referral
centers while some of the other studies obtained patients as part of clinical trials. The
observed differences may also simply reflect the inherent statistical shortcomings of
studying a limited patient sample. Although clearly not ready for clinical application, these
noteworthy findings provide a glimpse into the potential predictive power of using genetic
analysis to prospectively predict risk of cardiotoxicity in patients who may receive
anthracycline-based chemotherapy.
Toward a pharmacogenomic determination of risk
The power of the candidate-gene approach to predict a given genotype–phenotype
relationship is directly proportional to the degree to which the mechanistic determinants of
that phenotype have been identified. Our understanding of the mechanisms underlying the
cardiomyopathy that complicates trastuzumab and the tyrosine kinase inhibitors is likely too
narrow to inform effective candidate-gene efforts at risk profiling, although great strides are
being made in this area [60,71].
Conventional scientific wisdom has long held that doxorubicin-induced cardiotoxicity is
mediated largely by cell death in the setting of oxidative stress; however, the shortcomings
of that paradigm are becoming increasingly clear [19]. Newer technologies permitting
higher-throughput analysis have identified contributions from pathways that have not
previously been investigated. Proteomic analysis of the left ventricle of rabbits chronically
exposed to doxorubicin reveal distinct alterations in the mitochondrial metabolic signature,
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as well as altered abundance of key cytoskeletal and sarcomeric proteins in the setting of
activation of the proteasome system [72]. A genome-wide screen in doxorubicin-treated
yeast [73] and whole-genome linkage scans in human lymphoblastoid cell lines [74] have
also offered new glimpses into the complexity of the genetic determination of susceptibility
to doxorubicin-induced cytotoxicity. Whether these findings apply to human myocardial
biology remains to be seen, as there have been no large-scale efforts to query the human
genome for markers of risk for chemotherapeutic cardiotoxicity.
Genetic testing already guides dosing of multiple antineoplastic agents [75], and
chemotherapeutic cardiotoxicity seems a very promising target for broader
pharmacogenomic assessment. The adverse drug effect is highly morbid and is likely to
increase in frequency and severity as the number of patients with both heart disease and
cancer increases. The unpredictable and serious nature of doxorubicin-induced
cardiotoxicity has led to underuse of anthracyclines [76] and consideration of abandoning
this highly effective chemotherapeutic class altogether [77]. Indeed it is not hyperbolic to
observe that both the disease and the treatment itself carry life-threatening risk. There is
clear variability in susceptibility to myocardial damage that is incompletely explained by
clinical and demographic factors, and early evidence demonstrates genetic predisposition.
The identification of this complication prompts the discontinuation of otherwise effective
treatment, thus enhanced risk stratification could both minimize harm and maximize benefit.
Broader exploration for the genetic determinants of risk for chemotherapeutic cardiotoxicity
may even shed further light on the mechanisms underlying this unanticipated and highly
morbid adverse drug effect.
Future perspective
Chemotherapeutic cardiotoxicity appears ripe for further investigation. Indeed, a
subspecialty has recently been created for the study of this and related problems, such as
‘cardio-oncology’. Expanded preclinical molecular research will enhance our understanding
of the underlying mechanisms and novel nonhuman genetic resources will provide
opportunities for broader genomic analysis. Given the large volume of patients who receive
these medications and the relative frequency with which cardiotoxicity occurs, it seems
likely that human genome-wide association studies will be undertaken within the next
decade. Synthesis of these various approaches will undoubtedly lead to a deeper
understanding of the genetic determinants of chemotherapeutic cardiotoxicity. If such
studies identify variants that confer meaningful predisposition to cardiotoxicity, genetic
screening could be integrated with established clinical and demographic factors to mitigate
risk of developing this highly morbid adverse effect.
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Anthracyclines: the past & present of chemotherapeutic cardiotoxicity
• The anthracycline antibiotics, exemplified by doxorubicin (adriamycin), have
broad antineoplastic efficacy, but are associated with damage to the heart
(cardiotoxicity) that can be severe and permanent.
• Anthracycline-induced cardiotoxicity is partially dependent on cumulative dose,
but may occur at lower doses in patients with cardiac comorbidities or
idiosyncratically in patients with no obvious risk factors. In this article, we
present evidence that indicates a genetic predisposition to this important adverse
drug effect.
• Oxidative stress and apoptosis contribute to cardiomyocyte death, but the
mechanisms underlying anthracycline-induced cardiotoxicity are incompletely
understood.
The unanticipated cardiotoxicity of targeted therapies
• Newer antineoplastic agents with specific molecular targets also cause
cardiotoxicity. The best known of these drugs is trastuzumab, the humanized
monoclonal antibody to HER2 (also known as ErbB2).
• Multiple new drugs targeting tyrosine kinases also cause myocardial damage.
• The cardiotoxicity of targeted therapies results from both on-target and off-
target effects.
• Unlike anthracycline-induced cardiotoxicity, the cardiotoxicity of these agents is
entirely idiosyncratic and is often reversible. Older patients and those with
cardiac comorbidities are at greater risk for developing this adverse reaction.
Risk stratification: clinical & demographic profiling
• The likelihood of developing cardiotoxicity due to anthracyclines increases with
cumulative drug dose, concomitant radiation, age, sex and cardiovascular
comorbidities.
• Trastuzumab-induced cardiotoxicity appears to be independent of cumulative
dose, but occurs more often with concomitant doxorubicin administration and
cardiovascular comorbidities.
Risk stratification: candidate-gene approaches
• Variants in the genes encoding NADPH oxidase subunits and doxorubicin efflux
transporter ABCB1/MDR1 were found to increase risk for anthracycline-
induced cardiotoxicity in adults.
• A variant in the SLC28A3 gene conferred significant protection against
anthracycline-induced cardiotoxicity in a large candidate-gene study of
Canadian children. The investigators identified other protective variants and
developed a pediatric multigene risk prediction model.
Toward a pharmacogenomic determination of risk
• Candidate-gene approaches are limited by our incomplete understanding of the
mechanisms underlying chemotherapeutic cardiotoxicity. New proteomic and
genomic analyses of nonhuman organisms indicate the complexity of the genetic
determinants of this important adverse drug effect.
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• New ways to prospectively predict risk of chemotherapeutic cardiotoxicity are
needed. Pharmacogenomic approaches hold promise for minimizing cardiotoxic
harm and maximizing antineoplastic benefit associated with the use of
chemotherapeutic agents.
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Figure 1. Candidate genes for susceptibility to anthracycline-induced cardiotoxicity
Animal studies and limited human genetic analyses have identified candidate genes involved
in a limited number of processes that are central to the pathogenesis of anthracycline-
induced cardiotoxicity.
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Table 1
Antineoplastic agents associated with cardiotoxicity.
Antineoplastic agent Estimated prevalence of cardiotoxicity (%) Ref.
Adriamycin 5–15 (heart failure); ≤50 (subclinical cardiotoxicity) [10,11,13]
Trastuzumab 20–33 [43–45]
Sunitinib 8–15 (heart failure or cardiomyopathy) [52]
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